Actively Recruiting
Phase 2 Trial Evaluating Atezolizumab and Cabozantinib in Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma
Led by M.D. Anderson Cancer Center · Updated on 2026-10-06
40
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the combination of atezolizumab and cabozantinib in adolescents and young adults with recurrent or metastatic osteosarcoma. This phase II trial aims to measure how well this treatment controls the cancer by tracking progression-free survival, response rates, overall survival, and safety. The study also explores specific biomarkers and immune responses to better understand treatment effects. Participants receive atezolizumab by intravenous infusion on the first day of each 21-day cycle, while cabozantinib is taken orally once daily for 21 days. Cycles continue without disease progression or unacceptable side effects. After treatment ends, participants are followed up within 30 days and then every three months for two years to monitor their health and outcomes. During the study, participants undergo assessments including tumor biopsies, blood tests, and imaging to evaluate cancer progression and immune response. Researchers track side effects and measure survival outcomes for up to two years. The total participation duration includes treatment cycles and follow-up visits extending over two years after treatment completion.
CONDITIONS
Brief Title
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
Research Team
J
John A Livingston, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here